# Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

> **NCT02700334** · PHASE4 · COMPLETED · sponsor: **University of Guadalajara** · enrollment: 24 (actual)

## Conditions studied

- Prediabetes
- Impaired Fasting Glucose
- Impaired Glucose Tolerance

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02700334
- **Lead sponsor:** University of Guadalajara
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2017-01
- **Final completion:** 2017-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02700334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02700334, "Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02700334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*